AtriCure price target raised to $50 from $48 at Stifel

Stifel analyst Rick Wise raised the firm’s price target on AtriCure to $50 from $48 and keeps a Buy rating on the shares. The company’s "strong" Q1 performance was indicated to be impacted by the benefits from hospital staffing improvements, which drove better patient throughput, the analyst tells investors. Furthermore, the company increased its sales guidance, which, to Stifel, suggests there is room for upside as 2023 unfolds.